Cargando…
Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols
PURPOSE: The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targe...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527767/ https://www.ncbi.nlm.nih.gov/pubmed/34651290 http://dx.doi.org/10.1007/s11307-021-01656-3 |
_version_ | 1784801146005618688 |
---|---|
author | Wang, Cheng Xu, Xiaochun Folaron, Margaret Gunn, Jason R. Hodge, Sassan Chen, Eunice Y. Hoopes, P. Jack Tichauer, Kenneth M. Samkoe, Kimberley S. |
author_facet | Wang, Cheng Xu, Xiaochun Folaron, Margaret Gunn, Jason R. Hodge, Sassan Chen, Eunice Y. Hoopes, P. Jack Tichauer, Kenneth M. Samkoe, Kimberley S. |
author_sort | Wang, Cheng |
collection | PubMed |
description | PURPOSE: The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targeted agents and the variance of fluorescence signal. Paired-agent imaging (PAI) employs co-administration of an untargeted imaging agent with a molecular targeted agent, providing a normalization factor to minimize nonspecific and varied signals. The resulting measured binding potential is quantitative and equivalent to in vivo immunohistochemistry of the target protein. This study demonstrates that PAI improves the accuracy of tumor-to-healthy tissue discrimination compared to single-agent imaging for in vivo FGS. PROCEDURES: PAI using a fluorescent anti-epidermal growth factor receptor (EGFR) affibody molecule (ABY-029, eIND 122,681) with untargeted IRDye 700DX carboxylate was compared to ABY-029 alone in an oral squamous cell carcinoma xenograft mouse model at 3 h after dye administration (n = 30). RESULTS: PAI significantly enhanced tumor discrimination, as compared to ABY-029 alone in low EGFR-expressing tumors and highly heterogeneous populations including multiple cell lines with varying expression (diagnostic accuracy: 0.908 vs. 0.854 and 0.908 vs. 0.822; and ROC curve AUC: 0.963 vs. 0.909 and 0.957 vs. 0.909, respectively) indicating a potential for universal FGS image thresholds to determine surgical margins. In addition, PAI achieved significantly higher diagnostic ability than ABY-029 alone 0.25–5-h post injection and exhibited a stronger correlation to EGFR expression heterogeneity. CONCLUSION: The quantitative receptor delineation of PAI promises to improve the surgical therapeutic index of cancer resection in a clinically relevant timeline. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01656-3. |
format | Online Article Text |
id | pubmed-9527767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-95277672023-03-01 Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols Wang, Cheng Xu, Xiaochun Folaron, Margaret Gunn, Jason R. Hodge, Sassan Chen, Eunice Y. Hoopes, P. Jack Tichauer, Kenneth M. Samkoe, Kimberley S. Mol Imaging Biol Research Article PURPOSE: The goal of fluorescence-guided surgery (FGS) in oncology is to improve the surgical therapeutic index by enhancing contrast between cancerous and healthy tissues. However, optimal discrimination between these tissues is complicated by the nonspecific uptake and retention of molecular targeted agents and the variance of fluorescence signal. Paired-agent imaging (PAI) employs co-administration of an untargeted imaging agent with a molecular targeted agent, providing a normalization factor to minimize nonspecific and varied signals. The resulting measured binding potential is quantitative and equivalent to in vivo immunohistochemistry of the target protein. This study demonstrates that PAI improves the accuracy of tumor-to-healthy tissue discrimination compared to single-agent imaging for in vivo FGS. PROCEDURES: PAI using a fluorescent anti-epidermal growth factor receptor (EGFR) affibody molecule (ABY-029, eIND 122,681) with untargeted IRDye 700DX carboxylate was compared to ABY-029 alone in an oral squamous cell carcinoma xenograft mouse model at 3 h after dye administration (n = 30). RESULTS: PAI significantly enhanced tumor discrimination, as compared to ABY-029 alone in low EGFR-expressing tumors and highly heterogeneous populations including multiple cell lines with varying expression (diagnostic accuracy: 0.908 vs. 0.854 and 0.908 vs. 0.822; and ROC curve AUC: 0.963 vs. 0.909 and 0.957 vs. 0.909, respectively) indicating a potential for universal FGS image thresholds to determine surgical margins. In addition, PAI achieved significantly higher diagnostic ability than ABY-029 alone 0.25–5-h post injection and exhibited a stronger correlation to EGFR expression heterogeneity. CONCLUSION: The quantitative receptor delineation of PAI promises to improve the surgical therapeutic index of cancer resection in a clinically relevant timeline. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01656-3. Springer International Publishing 2021-10-14 2023 /pmc/articles/PMC9527767/ /pubmed/34651290 http://dx.doi.org/10.1007/s11307-021-01656-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Wang, Cheng Xu, Xiaochun Folaron, Margaret Gunn, Jason R. Hodge, Sassan Chen, Eunice Y. Hoopes, P. Jack Tichauer, Kenneth M. Samkoe, Kimberley S. Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols |
title | Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols |
title_full | Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols |
title_fullStr | Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols |
title_full_unstemmed | Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols |
title_short | Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols |
title_sort | improved discrimination of tumors with low and heterogeneous egfr expression in fluorescence-guided surgery through paired-agent protocols |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527767/ https://www.ncbi.nlm.nih.gov/pubmed/34651290 http://dx.doi.org/10.1007/s11307-021-01656-3 |
work_keys_str_mv | AT wangcheng improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT xuxiaochun improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT folaronmargaret improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT gunnjasonr improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT hodgesassan improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT cheneunicey improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT hoopespjack improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT tichauerkennethm improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols AT samkoekimberleys improveddiscriminationoftumorswithlowandheterogeneousegfrexpressioninfluorescenceguidedsurgerythroughpairedagentprotocols |